Alexion ( Alexion )


Alexion's picture

Alexion is a global biopharmaceutical company that combines groundbreaking science with a steadfast commitment to meeting the needs of patients living with severe, life-threatening and often ultra-rare diseases. Alexion scientists are among the first in the world to unlock the therapeutic potential of inhibiting terminal complement, a group of proteins that play an important role in the body's immune response and can destroy healthy tissue in certain patients.

Alexion press release, blog etc

06/27/2018 - 23:26 Alexion Submits Application for Approval of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in the European Union (EU)
06/19/2018 - 18:00 Alexion Submits Application for Priority Review and Approval of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in the U.S.
06/14/2018 - 13:31 Alexion Announces Selection of Positive Phase 3 Clinical Data for ALXN1210 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) for Late-Breaking Oral Presentation at Annual Conference of the European Hematology Association (EHA)
06/10/2018 - 20:38 Alexion and Complement Pharma Announce Partnership to Co-Develop Pre-Clinical Complement Inhibitor for Neurodegenerative Disorders
05/24/2018 - 23:02 Alexion Offer for Wilson Therapeutics Accepted
04/11/2018 - 00:27 Alexion to Acquire Wilson Therapeutics
03/15/2018 - 04:52 Alexion Announces Positive Top-Line Results Showing Successful Phase 3 Clinical Study of ALXN1210 in Complement Inhibitor Treatment-Naive Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
02/27/2018 - 07:07 The Manton Center at Boston Childrens Hospital and Alexion Pharmaceuticals Partner in Artificial Intelligence Approaches to Rare Disease Diagnosis
02/06/2018 - 17:13 Data Presented at WORLDSymposium 2018 Show Survival to 3 Years of Age and Improvements in Liver Function in Infants with Lysosomal Acid Lipase Deficiency Treated with Kanuma (sebelipase alfa)
02/05/2018 - 13:03 Alexion Appoints Judith A. Reinsdorf, J.D., to its Board of Directors
01/22/2018 - 03:14 Alexion Appoints Deborah Dunsire, M.D. to Its Board of Directors
01/02/2018 - 16:36 Alexion and Elliott Agree to Collaborate on Identifying a New Board Member
12/26/2017 - 05:49 Soliris (Eculizumab) Receives Marketing Authorization in Japan for the Treatment of Patients with Generalized Myasthenia Gravis (gMG)
12/11/2017 - 11:29 Results of Phase 1b/2 Dose Regimen Optimization Studies for ALXN1210 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Presented at American Society of Hematology (ASH) Meeting
11/09/2017 - 06:51 Alexion Employees Volunteer Together to Enhance Their Local Communities during Second Annual Global Day of Service
11/08/2017 - 17:33 Alexion Appoints Francois Nader, M.D. to its Board of Directors
11/06/2017 - 09:11 Alexion Receives New Japanese Patent for Soliris (eculizumab), Extending Patent Protection Into 2027 and Strengthening Global Patent Portfolio
11/03/2017 - 05:11 New Interim Data Presented at NASPGHAN 2017 Meeting Show Survival Beyond 1 Year of Age in Infants with LAL-D Treated with Kanuma (sebelipase alfa)